Claims for Patent: 9,034,324

Summary for Patent: 9,034,324

Title:	Anti-BCMA antibodies
Abstract:	This invention provides antibodies that recognize the B Cell Maturation Antigen (BCMA) and that bind naive B cells, plasma cells, and/or memory B cells. The invention further provides methods for depleting naive B cells, plasma cells, and memory B cells, and for treating B cell-related disorders, including lymphomas and autoimmune diseases.
Inventor(s):	Kalled; Susan L. (Concord, MA), Hsu; Yen-Ming (Lexington, MA)
Assignee:	BIOGEN IDEC MA INC. (Cambridge, MA)
Application Number:	13/255,610
Patent Claims:	1. An isolated antibody or antigen binding fragment thereof that binds to the polypeptide of SEQ ID NO:9, wherein the antibody or antigen binding fragment thereof comprises: a) a variable domain comprising CDR1, CDR2, and CDR3 of the amino acid sequence of SEQ ID NO:1 and a variable domain comprising CDR1, CDR2, and CDR3 of the amino acid sequence of SEQ ID NO:2; b) a variable domain comprising CDR1, CDR2, and CDR3 of the amino acid sequence of SEQ ID NO:3 and a variable domain comprising CDR1, CDR2, and CDR3 of the amino acid sequence of SEQ ID NO:4, SEQ ID NO:11, or SEQ ID NO:12; c) a variable domain comprising CDR1, CDR2, and CDR3 of the amino acid sequence of SEQ ID NO:5 and a variable domain comprising CDR1, CDR2, and CDR3 of the amino acid sequence of SEQ ID NO:6; or d) a variable domain comprising CDR1, CDR2, and CDR3 of the amino acid sequence of SEQ ID NO:7 and a variable domain comprising CDR1, CDR2, and CDR3 of the amino acid sequence of SEQ ID NO:8. 2. The antibody of claim 1, wherein the heavy chain variable domain comprises SEQ ID NO:5 and the light chain variable domain comprises SEQ ID NO:6. 3. The antibody of claim 1, wherein the antibody is a chimeric, humanized, or single chain antibody. 4. The antibody of claim 1, wherein the antibody comprises a variable domain comprising CDR1, CDR2, and CDR3 of the amino acid sequence of SEQ ID NO:1 and a variable domain comprising CDR1, CDR2, and CDR3 of the amino acid sequence of SEQ ID NO:2. 5. The antibody of claim 4, wherein the antibody comprises a variable domain of SEQ ID NO:1 and a variable domain of SEQ ID NO:2. 6. A hybridoma that produces the antibody of claim 1. 7. A pharmaceutical composition comprising the antibody of claim 1 and a pharmaceutically acceptable carrier. 8. A polypeptide that binds to SEQ ID NO:9 and comprises the antigen binding portion, Fab fragment, or F(ab')2 fragment of the antibody of claim 1. 9. A hybridoma that produces the antigen binding portion, Fab fragment, or F(ab')2 fragment of claim 8. 10. A pharmaceutical composition comprising the antigen binding portion, Fab fragment, or F(ab')2 fragment of claim 8 and a pharmaceutically acceptable carrier. 11. A method of depleting plasma cells which express BCMA, comprising administering the antibody of claim 1 or the polypeptide of claim 8 to a patient in need thereof. 12. A method of treating a B cell-related disorder associated with BCMA expression, comprising administering the antibody of claim 1 or the polypeptide of claim 8 to a patient in need thereof. 13. The method of claim 12, wherein the B-cell related disorder is plasmacytoma, Hodgkins' lymphoma, follicular lymphomas, small non-cleaved cell lymphomas, endemic Burkitt's lymphoma, sporadic Burkitt's lymphoma, marginal zone lymphoma, extranodal mucosa-associated lymphoid tissue lymphoma, nodal monocytoid B cell lymphoma, splenic lymphoma, mantle cell lymphoma, large cell lymphoma, diffuse mixed cell lymphoma, immunoblastic lymphoma, primary mediastinal B cell lymphoma, pulmonary B cell angiocentric lymphoma, small lymphocytic lymphoma, B cell proliferations of uncertain malignant potential, lymphomatoid granulomatosis, post-transplant lymphoproliferative disorder, an immunoregulatory disorder, rheumatoid arthritis, myasthenia gravis, idiopathic thrombocytopenia purpura, anti-phospholipid syndrome, Chagas' disease, Grave's disease, Wegener's granulomatosis, poly-arteritis nodosa, Sjogren's syndrome, pemphigus vulgaris, scleroderma, multiple sclerosis, anti-phospholipid syndrome, ANCA associated vasculitis, Goodpasture's disease, Kawasaki disease, autoimmune hemolytic anemia, and rapidly progressive glomerulonephritis, heavy-chain disease, primary or immunocyte-associated amyloidosis, or monoclonal gammopathy of undetermined significance. 14. The method of claim 13, wherein the B cell-related disorder is a B cell malignancy. 15. The method of claim 13, wherein the B cell-related disorder is a plasma cell malignancy. 16. The method of claim 15, wherein the plasma cell malignancy is multiple myeloma. 17. The method of claim 13, wherein the B cell-related disorder is an autoimmune disease. 18. The method of claim 17, wherein the autoimmune disease is systemic lupus erythematosus. 19. The method of claim 13, wherein the B-cell related disorder is rheumatoid arthritis. 20. The method of claim 13, wherein the B-cell related disorder is idiopathic thrombocytopenia purpura, or myasthenia gravis, or autoimmune hemolytic anemia. 21. The method of claim 11, further comprising administering rituximab. 22. A method of reducing the level of at least one autoantibody in a subject that expresses BCMA, comprising administering the antibody of claim 1 or the polypeptide of claim 8 to a patient in need thereof.

Details for Patent 9,034,324

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2029-03-10
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2029-03-10
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017		2029-03-10